Trial Profile
Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumour genetic heterogeneity.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Aug 2015 New trial record